NEWS & RESOURCES

01/08/2025

PrognomiQ Appoints Joel Kaufman as Chief Financial Officer

11/05/2024

PrognomiQ Announces $34 Million Series D Financing to Advance Development of Early Detection Test for Lung Cancer with Multi-omics Platform

01/08/2024

PrognomiQ’s Latest Research Demonstrates the Potential of its Multi-omics Liquid Biopsy Platform in Early-Stage Detection of Lung Cancer

08/09/2023

PrognomiQ Appoints Raj Garg to its Board of Directors

01/23/2023

PrognomiQ’s Multi-omics Liquid Biopsy Platform Demonstrates Promising Results in Early-Stage Cancer Detection of Non-Small Cell Lung Cancer

11/29/2022

PrognomiQ Strengthens its Scientific and Clinical Leadership with the Appointment of Brian Koh, M.D. as Chief Medical Officer

11/07/2024

​Prognomiq raises $34M for early lung cancer detection test

11/05/2024

PrognomiQ raises $34M for lung cancer test

05/16/2024

As Multiomics Progresses, Data Challenges Come to the Fore

05/16/2024

Lab-Testing Startups Brace for FDA Rule Change

05/11/2024

Philip Ma, CEO & Founder, PrognomiQ

04/19/2024

PrognomiQ Aims to Launch Multiomic Lung Cancer Screening Test Buoyed by Positive Early Data

January 2024

Multi-omics profiling with untargeted proteomics for blood-based early detection of lung cancer

October 2023

Multi-omic, plasma biomarkers for non-small cell lung cancer demonstrate strong performance for early cancer detection

September 2023

Deep, Multiomics, Bloodbased Biomarker Discovery In Current And Former Smokers Demonstrated High Early Detection Performance…

June 2023

timsTOF HT improves protein identification and quantitative reproducibility for deep unbiased plasma protein biomarker discovery

June 2023

Electrospray ionization source comparison and optimization on a capillary-flow SUREQUANT assay

June 2023

Dual-column ZenoTOF configuration to achieve robust and high-quality plasma proteomics

June 2023

Combination of the unique functions from timsTOF and ZenoTOF enables in-depth analysis of the glycoproteome

June 2023

Automated and scalable cloud-based computational pipeline for large-scale unbiased plasma proteomics study

June 2023

A comprehensive strategy for building DIA library and multi-aspect comparisons on SWATH data with ZenoTOF

May 2023

Biomarker discovery in non-small cell lung cancer enabled by deep multi‑omics profiling of proteins, metabolites,…

May 2023

A multi-omics classifier achieves high sensitivity and specificity for Pancreatic ductal adenocarcinoma in a case-control…

September 2022

High-Dimensional, Multi-Omics Analyses of Proteins, Metabolites, Transcripts, and Genes Enable Biomarker Discovery in Early- and…

June 2022

Combining Proteograph technology with Zeno SWATH acquisition enables the potential for deep, unbiased discovery of…

June 2022

An unbiased multi-omics approach for the detection of pancreatic cancer biomarkers utilizing ion-mobility mass spectrometry…

April 2022

Deep, unbiased multi-omics approach for identification of pancreatic cancer biomarkers from blood

March 2022

Incorporation of glycoproteome detection into large scale unbiased proteomics studies utilizing nanoparticles

November 2021

Large scale, deep, and unbiased proteomics profiling a sub-study of a multi-cancer cohort enabling biomarker…

2023

Fact Sheet